Table 3.

Key translational barriers and priority solutions for next-generation nanotherapeutics.

Translational barrier	Current limitation	Potential clinical consequence	Priority validation	Recommended next-generation solution
Insufficient disease and tissue specificity	Passive accumulation, vascular leak and phagocytic sequestration can be mislabeled as active targeting; target engagement is often not directly demonstrated.	Off-target exposure, incomplete efficacy and disruption of normal immune function	Absolute and dose-normalized biodistribution; cell-subset uptake; receptor-dependence/competition; target-engagement biomarkers.	Use disease- and stage-adapted ligands only when the target is validated in human tissue; distinguish accumulation from engagement.
Premature or poorly controlled drug release	Responsive release is often validated in simplified buffers or with trigger levels outside physiological/pathological ranges.	Low therapeutic index, dose escalation and systemic toxicity	Release in plasma and disease-relevant biofluids; overlapping normal/pathological pH, ROS or enzyme ranges; trigger-insensitive controls.	Calibrate triggers to measured human disease conditions and report premature leakage and on-target release quantitatively.
Long-term biocompatibility and accumulation	Repeated administration, cumulative organ exposure, immunogenicity, complement activation, degradation products and effects on normal immune function remain insufficiently characterized.	Delayed organ toxicity, chronic inflammation or immune dysfunction during long-term treatment	Risk-based toxicokinetics and organ-clearance assessment; targeted immunogenicity/complement testing where justified; degradation and recovery measures matched to material, cargo, route, and dosing schedule.	Design for material-specific clearance and characterize products of degradation; select longitudinal safety studies according to intended use and exposure.
Model-to-human disease mismatch	Short-term induced animal models often fail to reproduce patient heterogeneity, chronicity, relapse, multi-organ disease and treatment history	Inflated efficacy estimates and poor reproducibility in clinical development	Multiple complementary models; spontaneous/age-related or large-animal models where appropriate; human organoids and ex vivo tissues	Mechanism-informed translational model portfolios combined with patient-derived systems and multi-omics-guided target validation
Mechanistic fragmentation	Carrier and cargo effects are often conflated; M1/M2 readouts oversimplify macrophage states; collagen reduction may be presented as direct antifibrotic action.	Weak rationale for patient selection, dosing, combinations and long-term disease modification	Unloaded-carrier/free-cargo controls; single-cell/spatial profiling; pathway perturbation; myofibroblast, matrix-turnover and organ-function endpoints.	Mechanistic deconvolution and cell-state-resolved validation before claims of immune reprogramming or antifibrotic action.
Batch variability and manufacturing complexity	Complex synthesis, membrane coating or biological-vesicle production can generate variable size, cargo, surface composition and potency	Inconsistent efficacy/safety and difficulty meeting pharmaceutical quality requirements	Critical quality attributes; batch-release specifications; stability; potency assays; process comparability	Scalable modular manufacturing; standardized membrane/EV processing; fewer nonessential components; robust quality-by-design workflows
Incomplete pharmacokinetic and biodistribution characterization	Many studies emphasize efficacy while underreporting circulation, tissue residence, clearance and metabolite fate	Uncertain dose selection, treatment interval and organ-specific safety	Validated quantitative imaging/bioanalysis; PK/PD modeling; clearance pathways; repeated-dose distribution	Mechanism-linked PK/PD optimization and theranostic or traceable platforms where clinically justified
Regulatory and clinical evidence gaps	Complex nanomaterials require product-specific CMC, critical-quality-attribute, stability, potency and comparability packages; biomimetic/EV systems add source and batch variability.	Slow translation, uncertain comparability and difficulty designing first-in-human studies	GMP-compatible process; CQA specifications; potency assays; stability; comparability after scale-up; regulator-aligned nonclinical package.	Design for manufacturability early; simplify nonessential components; align development with FDA/EMA nanomedicine expectations.
Cost and implementation burden	Sophisticated multifunctional or patient-derived platforms may require expensive manufacturing, specialized storage and complex administration	Limited scalability and reduced accessibility even if biologically effective	Cost-of-goods modeling; shelf-life; transport/storage; administration feasibility	Clinically deployable designs with stable formulations, scalable inputs, practical dosing routes and explicit cost-effectiveness targets

ADME, absorption, distribution, metabolism and excretion; CMC, chemistry, manufacturing and controls; EV, extracellular vesicle; GMP, good manufacturing practice; PK/PD, pharmacokinetics/pharmacodynamics; ROS, reactive oxygen species.